These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10834040)

  • 1. Distorted spending priorities in Canada.
    Tyers GF
    CMAJ; 2000 May; 162(10):1402, 1404. PubMed ID: 10834040
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors.
    Hladik W; Kataaha P; Mermin J; Purdy M; Otekat G; Lackritz E; Alter MJ; Downing R
    Trop Med Int Health; 2006 Jun; 11(6):951-4. PubMed ID: 16772018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avoidable cost of alcohol abuse in Canada.
    Rehm J; Patra J; Gnam WH; Sarnocinska-Hart A; Popova S
    Eur Addict Res; 2011; 17(2):72-9. PubMed ID: 21150206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colon cancer screening.
    Kiberd B
    CMAJ; 2006 Mar; 174(7):975; author reply 975-6. PubMed ID: 16567760
    [No Abstract]   [Full Text] [Related]  

  • 5. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
    Plunkett BA; Grobman WA
    Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics of blood screening: in search of an optimal blood screening strategy.
    Chinkhumba J
    Trop Doct; 2006 Jan; 36(1):32-4. PubMed ID: 16483429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum pooling for screening of blood donors for hepatitis C virus antibody.
    Kini S; Kumar S; Sharma RR; Thakral B; Agnihotri SK
    Indian J Pathol Microbiol; 2003 Jul; 46(3):537-8. PubMed ID: 15025337
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health policy implications of the RAND medical outcomes study: improving the value of depression treatment.
    Sturm R; Wells KB
    Behav Healthc Tomorrow; 1996 Oct; 5(5):63-6. PubMed ID: 10161578
    [No Abstract]   [Full Text] [Related]  

  • 10. Trends in mental health cost growth: an expanded role for management?
    Frank RG; Goldman HH; McGuire TG
    Health Aff (Millwood); 2009; 28(3):649-59. PubMed ID: 19414870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for colorectal cancer: which test can we afford?
    Lansdorp-Vogelaar I; van Ballegooijen M; Kuipers EJ
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S38-40. PubMed ID: 18368641
    [No Abstract]   [Full Text] [Related]  

  • 12. [Economics and health policy: the example of hepatitis C viruses].
    Pol S; Berthelot P
    Gastroenterol Clin Biol; 1996; 20(12):1049-52. PubMed ID: 9033849
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mammography screening in Germany: how, when and why?].
    Bick U
    Rofo; 2006 Oct; 178(10):957-69. PubMed ID: 17021975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening blood donors for HTLV-1: a case for a cost-benefit analysis.
    West Indian Med J; 1990 Sep; 39(3):195-6. PubMed ID: 2124755
    [No Abstract]   [Full Text] [Related]  

  • 15. The necessity of accurate costs.
    Hankins S
    Am J Prev Med; 2009 Sep; 37(3):258-9. PubMed ID: 19666163
    [No Abstract]   [Full Text] [Related]  

  • 16. Screening for lung cancer: can it be cost-effective?
    Miettinen OS
    CMAJ; 2000 May; 162(10):1431-6. PubMed ID: 10834047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Organized hepatitis C screening. Results and cost of a one-year campaign in a pilot area].
    Monnet E; Mercet P; Woronoff-Lemsi MC; Bresson-Hadni S; Pruniaux J; Cottray P; Bouiller C; Allemand H; Miguet JP
    Gastroenterol Clin Biol; 2000 May; 24(5):541-6. PubMed ID: 10891743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The real costs of screening mammography.
    Levant MN
    CMAJ; 1999 Jul; 161(1):17-8. PubMed ID: 10420856
    [No Abstract]   [Full Text] [Related]  

  • 19. The real costs of screening mammography.
    Thurber L
    CMAJ; 1999 Jul; 161(1):17; author reply 18. PubMed ID: 10420855
    [No Abstract]   [Full Text] [Related]  

  • 20. Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening.
    Soderstrom L; Woods WG; Bernstein M; Robison LL; Tuchman M; Lemieux B
    J Natl Cancer Inst; 2005 Aug; 97(15):1118-24. PubMed ID: 16077069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.